Macrophage extrinsic antiviral activity during herpes simplex virus infection.
Peritoneal macrophages from mice infected with herpes simplex virus type 2 (HSV-2) exhibited extrinsic antiviral resistance. When the macrophages were co-cultivated in vitro with virus-infected cells the yield of virus was reduced markedly. Activity was not present 1 to 2 days p.i., peaked at 3 to 4 days, declined by 7 days and was absent at 14 days after HSV-2 infection. The extrinsic antiviral activity was limited to the adherent peritoneal macrophage population. The macrophage antiviral activity was also dose-dependent, with approx. 10(6) macrophages (macrophage: host cell ratio of approx. 2:1) reducing virus plaques by greater than 90% and virus yield 1.5 to 3.0 log10. Comparable extrinsic antiviral activity was also exhibited by Corynebacterium parvum- or thioglycollate-elicited peritoneal macrophages. The macrophage activity was not species-specific, activity on Vero cells or syngeneic mouse embryo fibroblasts being comparable. Activity was also not virus-specific, as the active macrophages also inhibited vesicular stomatitis virus (VSV). The antiviral effects required viable macrophages; cell lysates did not inhibit virus growth.
D000818:Animals; D001202:Ascitic Fluid / Q000166:cytology; D001428:Bacterial Vaccines; D002460:Cell Line; D003601:Cytotoxicity Tests, Immunologic; D005260:Female; D005347:Fibroblasts; D000882:Haplorhini; D006561:Herpes Simplex / Q000276:immunology*; D066298:In Vitro Techniques; D007668:Kidney; D008264:Macrophages / Q000276:immunology*; D008297:Male; D051379:Mice; D011425:Propionibacterium acnes / Q000276:immunology; D018139:Simplexvirus / Q000254:growth & development / Q000276:immunology*; D013864:Thioglycolates; D014721:Vesicular stomatitis Indiana virus / Q000276:immunology; D014779:Virus Replication
D001428:Bacterial Vaccines; D013864:Thioglycolates